Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cns Pharmaceuticals Inc
(NQ:
CNSP
)
0.1220
+0.0022 (+1.84%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cns Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Novel Type of Immunotherapy Exhibits Efficacy Against Brain Tumors in Mouse Models
October 02, 2023
Via
Investor Brand Network
Surgical Robot Prototype Could Ease Pediatric Brain Cancer Surgery
September 26, 2023
Via
Investor Brand Network
Trial Enrollment Growth Supports Plans of CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) to Complete Enrollment for Important Brain Cancer Drug Study
September 25, 2023
Via
Investor Brand Network
Nottingham University Researchers Find Way to Make Brain Cancer Cells Self-Destruct
September 20, 2023
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Optimistic Berubicin May Provide Much-Needed Benefit for GBM Patients
September 15, 2023
Via
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023
Via
ACCESSWIRE
CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Reiterates Upcoming Milestones
August 14, 2023
Via
ACCESSWIRE
Microdevices to Enable Simultaneous Multiple Studies on Potential Brain Cancer Treatments
September 14, 2023
Via
Investor Brand Network
Study Shares Insights on Why Brain Tumors Are Unresponsive to Immunotherapy
September 11, 2023
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Looking Forward to Upcoming Interim Results for Potentially Pivotal GBM Study
September 08, 2023
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces 200-Patient Enrollment Milestone in Potentially Pivotal Berubicin Study
September 07, 2023
Via
Investor Brand Network
CNS Pharmaceuticals to Present at Benzinga's Virtual Biotech Conference
August 03, 2023
Via
ACCESSWIRE
Researchers Trace Glioma Brain Tumor Origins to Epigenome
July 31, 2023
Via
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Reaches Milestone with Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (GBM)
September 07, 2023
Via
ACCESSWIRE
Policies Encouraging High-Volume Facilities Disadvantage Oncology Patients in Rural Areas
September 05, 2023
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at Upcoming H.C. Wainwright Global Investment Conference
September 05, 2023
Via
Investor Brand Network
AI Helps Forecast Brain Tumor Outcomes
August 29, 2023
Via
Investor Brand Network
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Canadian Researchers Design Powerful Imaging Tech to Boost Cancer Fight
August 23, 2023
Via
Investor Brand Network
Researchers Develop Novel Way to Detect Pediatric Brain-Cancer Mutations
August 17, 2023
Via
Investor Brand Network
How Healthcare eCommerce Impacts Traditional Providers of Healthcare
August 14, 2023
Via
Investor Brand Network
Exposures
COVID-19
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q2 2023 Results, Presents Updated Findings from Potentially Pivotal Study of Berubicin
August 14, 2023
Via
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
August 14, 2023
Via
ACCESSWIRE
Israeli Company Seeks to Develop Micro-Robots to Boost Precision Medicine
August 10, 2023
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Distinguished with Unique Capabilities
August 07, 2023
Via
Investor Brand Network
Exposures
COVID-19
Researchers Unlock Previously Unknown Weakness of Brain Cancer
August 04, 2023
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports on Berubicin Pivotal Study, Announces Participation in Biotech Conference
August 03, 2023
Via
Investor Brand Network
CNS Pharmaceuticals Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
August 03, 2023
Via
ACCESSWIRE
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Abstract Selected for Poster Presentation at 2023 SNO/ASCO CNS Cancer Conference
July 27, 2023
Via
Investor Brand Network
CNS Pharmaceuticals (NASDAQ:CNSP) Announces Acceptance of Abstract for Poster Presentation at the 2023 SNO/ASCO CNS Cancer Conference
July 27, 2023
Via
ACCESSWIRE
Clinical Trial Testing Modified Viruses as Brain Cancer Treatment Begins
July 25, 2023
Via
Investor Brand Network
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.